How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

J Clin Oncol. 2011 Sep 10;29(26):3591-2; author reply 3592-3. doi: 10.1200/JCO.2011.36.5759. Epub 2011 Aug 15.

Authors

Julie R Gralow, Allan Lipton, Alison T Stopeck

PMID: 21844502
DOI: 10.1200/JCO.2011.36.5759

No abstract available

Publication types

Letter
Comment

MeSH terms

Bone Density Conservation Agents / therapeutic use*
Bone Neoplasms / drug therapy*
Breast Neoplasms / drug therapy*
Female
Humans

Substances

Bone Density Conservation Agents